ARLINGTON, Va., Feb. 19, 2019 /PRNewswire-PRWeb/ -- BioInformatics Inc., part of Science and Medicine Group, today announced the appointment of Mark Hozza as Chief Commercial Officer of the life science research and advisory firm. As the leader of the sales organization, Mark is responsible for the performance, strategy, and alignment of all market research and media revenue operations in the company. Mark's responsibilities will span the entire breadth of Science and Medicine Group's industry coverage, including life science, analytical instruments, clinical diagnostics, medical imaging, and dental products.
"Mark is a global executive who has spearheaded multi-million dollar growth within numerous industries. His approach to business is rooted in tenets of trust, transparency, and cross-functional cohesion and is a perfect fit for our business model," said Craig Overpeck, CEO of Bioinformatics Inc."
Mark has held senior positions at Bruker BioSpin Corporation, Tecan US Inc., Orchid Biosciences, and Merck & Co Inc. "Business is all about relationships and people," said Hozza. "I am excited about this opportunity to build on BioInformatics' longstanding relationships with life science companies and extend this respected brand into new markets."
ABOUT BIOINFORMATICS INC.
BioInformatics Inc., part of Science and Medicine Group, is the premier research and advisory firm serving the life science, clinical diagnostics, and analytical instrument industries. By leveraging our expert network of more than 50,000 life scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
MEDIA CONTACT:
Monika Mahajani
Content Marketing Associate
BioInformatics Inc.
671 N. Glebe Road, Suite 1610
Arlington, VA 22203
703.778.3080 x37
[email protected]
SOURCE BioInformatics Inc.
Share this article